SSI Strategy, founded to address the specialized needs of the life sciences sector, is a boutique management consulting firm focusing on Medical Affairs, Pharmacovigilance, and Clinical Development. The company’s mission is to provide expert guidance and strategic support to pharmaceutical companies, leveraging the extensive industry experience of its team members. SSI Strategy aims to enhance the efficiency and effectiveness of its clients' medical and clinical operations, ensuring better outcomes in drug development and patient safety.
Notably, SSI Strategy has merged with NDA Group, expanding its capabilities and reach within the regulatory and consulting landscape. The firm is composed of seasoned pharmaceutical industry leaders and adept business consultants, which has enabled it to achieve significant milestones in improving clinical and medical functions for its clients. This merger signifies a strengthened position in the market, enhancing SSI Strategy's impact on the life sciences industry by combining regulatory expertise with strategic consulting services.
